Health Care·Biotechnology·$5.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.65 | N/A | -21.95% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -$0.65 | N/A | -21.95% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to progressing their clinical pipeline.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing their clinical programs despite the financial loss.
Scholar Rock's earnings report shows a significant loss per share, which was below expectations. Despite this, the stock rose by 2.25%, likely due to investor optimism about the company's ongoing clinical programs. The lack of revenue data and guidance may leave some investors cautious moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DISNEY WALT CO
Aug 4, 2020